Back to top
more

Lexicon Pharmaceuticals (LXRX)

(Delayed Data from NSDQ)

$1.67 USD

1.67
1,512,698

+0.01 (0.60%)

Updated Jul 5, 2024 04:00 PM ET

After-Market: $1.67 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (82 out of 249)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for LXRX

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

1 item in cart

View Cart/Checkout

Lexicon Pharmaceuticals, Inc. [LXRX]

Reports for Purchase

Showing records 261 - 280 ( 393 total )

Company: Lexicon Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 261

11/04/2014

Daily Note

Pages: 46

November and Remaining 2014 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 100.00

Research Provided by a Third Party

Company: Lexicon Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 262

10/22/2014

Company Report

Pages: 7

Commercialization Agreement Announced with Ipsen for Lexicon''s Phase 3 Product, Telotristat Etiprate; Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Lexicon Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 263

10/22/2014

Company Report

Pages: 2

Announced a partnership with Paris-based Ipsen for the ex-North America/Japan rights to telotristat etiprate.

Provider: G.RESEARCH, LLC

Analyst: KEDRA K

Price: 10.00

Research Provided by a Third Party

Company: Lexicon Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 264

10/01/2014

Daily Note

Pages: 46

October and Remaining 2014 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 100.00

Research Provided by a Third Party

Company: Lexicon Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 265

08/26/2014

Daily Note

Pages: 46

September and Remaining 2014 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 100.00

Research Provided by a Third Party

Company: Lexicon Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 266

08/19/2014

Company Report

Pages: 6

We are lowering our recommendation to a Hold

Provider: G.RESEARCH, LLC

Analyst: KEDRA K

Price: 25.00

Research Provided by a Third Party

Company: Lexicon Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 267

08/13/2014

Industry Report

Pages: 15

LIFE SCIENCES AND HEALTH CARE-2014 LSMAC Day 1

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 50.00

Research Provided by a Third Party

Company: Lexicon Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 268

08/13/2014

Daily Note

Pages: 15

2014 LSMAC Day 1

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 50.00

Research Provided by a Third Party

Company: Lexicon Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 269

08/08/2014

Industry Report

Pages: 47

Emerging Pharmaceuticals - August and 2014 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 100.00

Research Provided by a Third Party

Company: Lexicon Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 270

08/07/2014

Company Report

Pages: 8

Q2 Earnings In Line and Pipeline Progressing on Time; Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Lexicon Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 271

07/27/2014

Industry Report

Pages: 6

LIFE SCIENCES AND HEALTH CARE

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Lexicon Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 272

07/14/2014

Industry Report

Pages: 6

The Week Ahead in Life Sciences - Upcoming Events for the Week of July 14

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Lexicon Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 273

07/09/2014

Daily Note

Pages: 6

JDRF Supports Next Phase II Trial of LX4211 for the Treatment of T1DM in Young Adults

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Lexicon Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 274

07/09/2014

Company Report

Pages: 2

New CEO - Buy

Provider: G.RESEARCH, LLC

Analyst: KEDRA K

Price: 10.00

Research Provided by a Third Party

Company: Lexicon Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 275

07/08/2014

Daily Note

Pages: 6

Industry Veteran Lonnel Coats Appointed as New President and CEO of Lexicon

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Lexicon Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 276

07/08/2014

Daily Note

Pages: 6

Industry Veteran Lonnel Coats Appointed as New President and CEO of Lexicon; Reiterate OUTPERFORM and $4 PT

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Lexicon Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 277

07/02/2014

Industry Report

Pages: 48

July and 2014 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 100.00

Research Provided by a Third Party

Company: Lexicon Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 278

06/16/2014

Daily Note

Pages: 6

Shows Efficacy in T2DM with Renal Impairment;Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Lexicon Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 279

06/16/2014

Daily Note

Pages: 6

LX4211 Shows Efficacy in T2DM with Renal Impairment;Reiterate OUTPERFORM and $ 4 PT

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Lexicon Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 280

06/02/2014

Daily Note

Pages: 47

June and 2014 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 100.00

Research Provided by a Third Party